Yoshida E, Fujimura Y, Miura S, Sugimoto M, Fukui H, Narita N, Usami Y, Suzuki M, Titani K
Department of blood transfusion, Nara Medical College, Japan.
Biochem Biophys Res Commun. 1993 Mar 31;191(3):1386-92. doi: 10.1006/bbrc.1993.1371.
Alboaggregin-B (AL-B) (Peng et al., Biochemistry (1991) 30, 11529-11536) was highly purified from the snake venom of Trimeresurus albolabris and characterized structurally and functionally, comparing with botrocetin, another snake venom protein recently characterized (Usami et al., Proc. Natl. Acad. Sci. USA (1993) 90, 928-932). Both the venom proteins are a heterodimer and show a high degree of sequence homology to each other and also to C-type lectins. Botrocetin specifically binds to von Willebrand factor (vWF), whereas AL-B binds to platelet glycoprotein (GP) Ib without affecting the binding of botrocetin to vWF. The binding of AL-B to GPIb does not potentiate the platelet aggregation even by exogenous fibrinogen, suggesting that AL-B binding to GPIb does not activate GPIIb/IIIa complex.
白环蛇凝集素-B(AL-B)(Peng等人,《生物化学》(1991年)30卷,11529 - 11536页)是从白唇竹叶青蛇毒中高度纯化得到的,并对其进行了结构和功能表征,同时与另一种最近表征的蛇毒蛋白博曲洛菌素(Usami等人,《美国国家科学院院刊》(1993年)90卷,928 - 932页)进行了比较。这两种蛇毒蛋白均为异二聚体,彼此之间以及与C型凝集素都显示出高度的序列同源性。博曲洛菌素特异性结合血管性血友病因子(vWF),而AL-B结合血小板糖蛋白(GP)Ib,且不影响博曲洛菌素与vWF的结合。即使存在外源性纤维蛋白原,AL-B与GPIb的结合也不会增强血小板聚集,这表明AL-B与GPIb的结合不会激活GPIIb/IIIa复合物。